Summary: PathAI adds CE-IVDR marking for AISight Dx

Why It Matters: PathAI is expanding its reach into the European market. This new regulatory mark allows them to sell their digital pathology platform for clinical use in Europe, not just the United States.

What Changed:

• Added a new product listing for AISight Dx Digital Pathology Platform with CE-IVDR marking.
• Created a specific website link for the European version of the AISight Dx solution.
• Updated the copyright year and internal marketing tracking codes in the footer.